Atopic dermatitis

Lancet

Volumn 361, Issue 9352, 2003, Pages 151-160

  Leung, Donald Y M ^a,b   Bieber, Thomas ^c  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTIMETABOLITE; AZATHIOPRINE; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLOXACILLIN; CYCLOSPORIN A; CYTOKINE; DICLOXACILLIN; ERYTHROMYCIN; FOOD ALLERGEN; FUSIDIC ACID; GAMMA INTERFERON; GLUCOCORTICOID; HERBACEOUS AGENT; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXACILLIN; PHOSPHODIESTERASE INHIBITOR; PIMECROLIMUS; PSEUDOMONIC ACID;

ADOPTIVE IMMUNOTHERAPY; ANTIBIOTIC THERAPY; ANTIGEN PRESENTING CELL; ATOPIC DERMATITIS; CELL INFILTRATION; CLINICAL FEATURE; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; EMOTIONAL STRESS; GENETIC DISORDER; HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY CELL; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARE; STAPHYLOCOCCUS AUREUS;

EID: 0037431756     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12193-9     Document Type: Conference Paper

References (100)

1. Bieber T., Leung D.Y.M. Atopic dermatitis. 2002;Marcel Dekker, New York.
2. Johansson S.G., Hourihane J.O., Bousquet J., et al. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy. 56:2001;813-824.
3. Schultz-Larsen F., Hanifin J.M. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am. 22:2002;1-24.
4. Taylor B., Wadsworth J., Wadsworth M., Peckham C. Changes in the reported prevalence of childhood eczema since the 1939-45 war. Lancet. 2:1984;1255-1257.
5. Williams H., Robertson C., Stewart A., et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 103:1999;125-138.
6. Schäfer T., Krämer U., Vieluf D., Abeck D., Behrendt H., Ring J. The excess of atopic eczema in East Germany is related to the intrinsic type. Br J Dermatol. 143:2000;992-998.
7. von Mutius E. The environmental predictors of allergic disease. J Allergy Clin Immunol. 105:2000;9-19.
8. Romagnani S. The role of lymphocytes in allergic disease. J Allergy Clin Immunol. 105:2000;399-408.
9. Williams H.C. Diagnostic criteria for atopic dermatitis: where do we go from here? Arch Dermatol. 135:1999;583-586.
10. Leung D.Y. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol. 105:2000;860-876.
11. Saurat J.H. Eczema in primary immune-deficiencies: clues to the pathogenesis of atopic dermatitis with special reference to the Wiskott-Aldrich syndrome. Acta Derm Venereol Suppl. 114:1985;125-128.
12. Woodward A.L., Spergel J.M., Alenius H., et al. An obligate role for T-cell receptor alphabeta+ T cells but not T-cell receptor gammadelta+ T cells, B cells, or CD40/CD40L interactions in a mouse model of atopic dermatitis. J Allergy Clin Immunol. 107:2001;359-366.
13. Beck L.A., Leung D.Y. Allergen sensitization through the skin induces systemic allergic responses. J Allergy Clin Immunol. 106:(suppl):2000;S258-263.
14. Higashi N., Gesser B., Kawana S., Thestrup-Pedersen K. Expression of IL-18 mRNA and secretion of IL-18 are reduced in monocytes from patients with atopic dermatitis. J Allergy Clin Immunol. 108:2001;607-614.
15. van Reijsen F.C., Bruijnzeel-Koomen C.A., Kalthoff F.S., et al. Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol. 90:1992;184-193.
16. Spergel J.M., Mizoguchi E., Brewer J.P., Martin T.R., Bhan A.K., Geha R.S. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest. 101:1998;1614-1622.
17. Hanifin J.M., Chan S.C., Cheng J.B., et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 107:1996;51-56.
18. Jirapongsananuruk O., Hofer M.F., Trumble A.E., Norris D.A., Leung D.Y. Enhanced expression of B7.2 (CD86) in patients with atopic dermatitis: a potential role in the modulation of IgE synthesis. J Immunol. 160:1998;4622-4627.
19. Mihm M.C. Jr, Soter N.A., Dvorak H.F., Austen K.F. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol. 67:1976;305-312.
20. Leung D.Y., Bhan A.K., Schneeberger E.E., Geha R.S. Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol. 71:1983;47-56.
21. Wollenberg A., Kraft S., Hanau D., Bieber T. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol. 106:1996;446-453.
22. Hamid Q., Boguniewicz M., Leung D.Y. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest. 94:1994;870-876.
23. Hamid Q., Naseer T., Minshall E.M., Song Y.L., Boguniewicz M., Leung D.Y. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol. 98:1996;225-231.
24. Grewe M., Bruijnzeel-Koomen C.A., Schopf E., et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today. 19:1998;359-361.
25. Trautmann A., Akdis M., Schmid-Grendelmeier P., et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol. 108:2001;839-846.
26. Novak N., Kraft S., Bieber T. IgE receptors. Curr Opin Immunol. 13:2001;721-726.
27. von Bubnoff D., Geiger E., Bieber T. Antigen-presenting cells in allergy. J Allergy Clin Immunol. 108:2001;329-339.
28. Langeveld-Wildschut E.G., Bruijnzeel P.L., et al. Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions. J Allergy Clin Immunol. 105:2000;1008-1016.
29. Laberge S., Ghaffar O., Boguniewicz M., Center D.M., Leung D.Y., Hamid Q. Association of increased CD4+ T-cell infiltration with increased IL-16 gene expression in atopic dermatitis. J Allergy Clin Immunol. 102:1998;645-650.
30. Reich K., Hugo S., Middel P., Blaschke V., et al. Evidence for a role of Langerhans cell-derived IL-16 in atopic dermatitis. J Allergy Clin Immunol. 109:2002;681-687.
31. Taha R.A., Minshall E.M., Leung D.Y., et al. Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. J Allergy Clin Immunol. 105:2000;1002-1007.
32. Yawalkar N., Uguccioni M., Scharer J., et al. Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest Dermatol. 113:1999;43-48.
33. Morales J., Homey B., Vicari A.P., et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA. 96:1999;14470-14475.
34. Galli G., Chantry D., Annunziato F., et al. Macrophage-derived chemokine production by activated human T cells in vitro and in vivo: preferential association with the production of type 2 cytokines. Eur J Immunol. 30:2000;204-210.
35. Kakinuma T., Nakamura K., Wakugawa M., et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 107:2001;535-541.
36. Nakatani T., Kaburagi Y., Shimada Y., et al. CCR4 memory CD4+ T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitis. J Allergy Clin Immunol. 107:2001;353-358.
37. Bratton D.L., Hamid Q., Boguniewicz M., Doherty D.E., Kailey J.M., Leung D.Y. Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis. J Clin Invest. 95:1995;211-218.
38. Nickoloff B.J., Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol. 30:1994;535-546.
39. Giustizieri M.L., Mascia F., Frezzolini A., et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol. 107:2001;871-877.
40. Soumelis V., Reche P.A., Kanzler H., et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 3:2002;673-680.
41. Forrest S., Dunn K., Elliott K., et al. Identifying genes predisposing to atopic eczema. J Allergy Clin Immunol. 104:1999;1066-1070.
42. Kawashima T., Noguchi E., Arinami T., et al. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese famillies. J Med Genet. 35:1998;502-504.
43. Cox H.E., Moffatt M.F., Faux J.A., et al. Association of atopic dermatitis to the beta subunit of the high affinity immunoglobulin E receptor. Br J Dermatol. 138:1998;182-187.
44. Arkwright P.D., Chase J.M., Babbage S., Pravica V., David T.J., Hutchinson I.V. Atopic dermatitis is associated with a low-producer transforming growth factor beta(1) cytokine genotype. J Allergy Clin Immunol. 108:2001;281-284.
45. Lee Y.A., Wahn U., Kehrt R., et al. A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat Genet. 26:2000;470-473.
46. Cookson W.O., Ubhi B., Lawrence R., et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet. 27:2001;372-373.
47. Sampson H.A. Food allergy. Part 1: immunopathogenesis and clinical disorders. J Allergy Clin Immunol. 103:1999;717-728.
48. Lever R., MacDonald C., Waugh P., Aitchison T. Randomised controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs. Pediatr Allergy Immunol. 9:1998;13-19.
49. van Reijsen F.C., Felius A., Wauters E.A., Bruijnzeel-Koomen C.A., Koppelman S.J. T-cell reactivity for a peanut-derived epitope in the skin of a young infant with atopic dermatitis. J Allergy Clin Immunol. 101:1998;207-209.
50. Li X.M., Kleiner G., Huang C.K., et al. Murine model of atopic dermatitis associated with food hypersensitivity. J Allergy Clin Immunol. 107:2001;693-702.
51. Tupker R.A., De Monchy J.G., Coenraads P.J., Homan A., van der Meer J.B. Induction of atopic dermatitis by inhalation of house dust mite. J Allergy Clin Immunol. 97:1996;1064-1070.
52. Wheatley L.M., Platts-Mills T.A.E. Role of inhalant allergens in atopic dermatitis. Leung D.Y.M., Greaves M.W. Allergic skin disease: a multidisciplinary approach. 2000;423 Marcel Dekker, New York.
53. Tan B.B., Weald D., Strickland I., Friedmann P.S. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet. 347:1996;15-18.
54. Holm L., Bengtsson A., van Hage-Hamsten M., Ohman S., Scheynius A. Effectiveness of occlusive bedding in the treatment of atopic dermatitis - a placebo-controlled trial of 12 months' duration. Allergy. 56:2001;152-158.
55. Scalabrin D.M., Bavbek S., Perzanowski M.S., Wilson B.B., Platts-Mills T.A., Wheatley L.M. Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol. 104:1999;1273-1279.
56. Keller P. Beitrag zu den Beziehungen von Asthma und Ekzem. Arch Derm Syph Berl. 148:1924;82.
57. Valenta R., Seiberler S., Natter S., et al. Autoallergy: a pathogenetic factor in atopic dermatitis? J Allergy Clin Immunol. 105:2000;432-437.
58. Valenta R., Natter S., Seiberler S., et al. Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. J Invest Dermatol. 111:1998;1178-1183.
59. Kinaciyan T., Natter S., Kraft D., Stingl G., Valenta R. IgE autoantibodies monitored in a patient with atopic dermatitis under cyclosporin A treatment reflect tissue damage. J Allergy Clin Immunol. 109:2002;717-719.
60. Leyden J.J., Kligman A.M. The case for steroid-antibiotic combinations. Br J Dermatol. 96:1977;179-187.
61. Leung D.Y., Harbeck R., Bina P., et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest. 92:1993;1374-1380.
62. Breuer K., Wittmann M., Bosche B., Kapp A., Werfel T. Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). Allergy. 55:2000;551-555.
63. Bunikowski R., Mielke M.E., Skarabis H., et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol. 105:2000;814-819.
64. Strickland I., Hauk P.J., Trumble A.E., Picker L.J., Leung D.Y. Evidence for superantigen involvement in skin homing of T cells in atopic dermatitis. J Invest Dermatol. 112:1999;249-253.
65. Hofer M.F., Harbeck R.J., Schlievert P.M., Leung D.Y. Staphylococcal toxins augment specific IgE responses by atopic patients exposed to allergen. J Invest Dermatol. 112:1999;171-176.
66. Hauk P.J., Hamid Q.A., Chrousos G.P., Leung D.Y. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol. 105:2000;782-787.
67. Skov L., Olsen J.V., Giorno R., Schlievert P.M., Baadsgaard O., Leung D.Y. Application of Staphylococcal enterotoxin B on normal and atopic skin induces up-regulation of T cells by a superantigen-mediated mechanism. J Allergy Clin Immunol. 105:2000;820-826.
68. Nilsson E.J., Henning C.G., Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol. 27:1992;29-34.
69. Remitz A., Kyllonen H., Granlund H., Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol. 107:2001;196-197.
70. Cho S.H., Strickland I., Tomkinson A., Fehringer A.P., Gelfand E.W., Leung D.Y. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol. 116:2001;658-663.
71. Cho S.H., Strickland I., Boguniewicz M., Leung D.Y. Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol. 108:2001;269-274.
72. Ong P.Y., Ohtake T., Brandt C., et al. Decreased antimicrobial peptides contribute to increased infections in atopic dermatitis. N Engl J Med. 347:2002;1151-1160.
73. Hoare C., Li Wan Po A., Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 4:2000;1-191.
74. Imokawa G. Lipid abnormalities in atopic dermatitis. J Am Acad Dermatol. 45:(suppl):2001;S29-32.
75. Woodmansee D.P., Christiansen S.C. Improvement in atopic dermatitis in infants with the introduction of an elemental formula. J Allergy Clin Immunol. 108:2001;309.
76. Van Der Meer J.B., Glazenburg E.J., Mulder P.G., Eggink H.F., Coenraads P.J. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol. 140:1999;1114-1121.
77. Wollenberg A., Sharma S., von Bubnoff D., Geiger E., Haberstok J., Bieber T. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol. 107:2001;519-525.
78. Reitamo S., Van Leent E.J., Ho V., et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 109:2002;539-546.
79. Reitamo S., Rustin M., Ruzicka T., et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 109:2002;547-555.
80. Paller A., Eichenfield L.F., Leung D.Y., Stewart D., Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 44:(suppl):2001;S47-57.
81. Kang S., Lucky A.W., Parisen D., et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 44:(suppl):2001;S58-64.
82. Allen A., Siegfried E., Silverman R., et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. 137:2001;747-750.
83. Zuberbier T., Chong S.U., Grunow K., et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol. 108:2001;275-280.
84. Luger T., Van Leent E.J., Graeber M., et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 144:2001;788-794.
85. Eichenfield L.F., Lucky A.W., Boguniewicz M., et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 46:2002;495-504.
86. Kapp A., Papp K., Bingham A., et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol. 110:2002;277-284.
87. Boguniewicz M., Sampson H., Leung S.B., Harbeck R., Leung D.Y. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol. 108:2001;651-652.
88. Ambach A., Bonnekoh B., Gollnick H. Perforin hyperreleasability and depletion in cytotoxic T cells from patients with exacerbated atopic dermatitis and asymptomatic rhinoconjunctivitis allergica. J Allergy Clin Immunol. 107:2001;878-886.
89. Zargari A., Eshaghi H., Back O., Johansson S., Scheynius A. Serum IgE reactivity to Malassezia furfur extract and recombinant M furfur allergens in patients with atopic dermatitis. Acta Derm Venereol. 81:2001;418-422.
90. Krutmann J., Diepgen T.L., Luger T.A., et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol. 38:1998;589-593.
91. Reynolds N.J., Franklin V., Gray J.C., Diffey B.L., Farr P.M. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet. 357:2001;2012-2016.
92. Simons F.E. Prevention of acute urticaria in young children with atopic dermatitis. J Allergy Clin Immunol. 107:2001;703-706.
93. Hanifin J.M., Schneider L.C., Leung D.Y., et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol. 28:1993;189-197.
94. Sowden J.M., Berth-Jones J., Ross J.S., et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 338:1991;137-140.
95. Grundmann-Kollmann M., Podda M., Ochsendorf F., Boehncke W.H., Kaufmann R., Zollner T.M. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol. 137:2001;870-873.
96. Schmid-Ott G., Jaeger B., Meyer S., Stephan E., Kapp A., Werfel T. Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison with healthy controls. J Allergy Clin Immunol. 108:2001;455-462.
97. Schmid-Ott G., Jaeger B., Adamek C., et al. Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol. 107:2001;171-177.
98. Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol. 27:2002;3-7.
99. Koo J., Arain S. Traditional Chinese medicine for the treatment of dermatologic disorders. Arch Dermatol. 134:1998;1388-1393.
100. Keane F.M., Munn S.E., du Vivien A.W., Taylor N.F., Higgins E.M. Analysis of Chinese herbal creams prescribed for dematological conditions. BMJ. 318:1999;563-564.